[EN] COMPOUNDS THAT INHIBIT NF?B ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ DE NF?B
申请人:UNIV COLUMBIA
公开号:WO2010051064A1
公开(公告)日:2010-05-06
The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation
作者:Yuli Xie、ShiXian Deng、Craig J. Thomas、Yidong Liu、Ya-Qin Zhang、Alison Rinderspacher、Wenwei Huang、Gangli Gong、Michael Wyler、Efithia Cayanis、Nathalie Aulner、Udo Többen、Caty Chung、Sergey Pampou、Noel Southall、Dušica Vidović、Stephan Schürer、Lars Branden、R. Eric Davis、Louis M. Staudt、James Inglese、Christopher P. Austin、Donald W. Landry、Deborah H. Smith、Douglas S. Auld
DOI:10.1016/j.bmcl.2007.10.100
日期:2008.1
We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NF kappa B pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in both primary and secondary assays of NF kappa B activation and expanded upon through analogue synthesis. The series exhibited potencies in the cell-based assays at as low as 0.6 mu M, and several indications suggest that the targeted activity lies within a common region of the NF kappa B pathway. (C) 2007 Elsevier Ltd. All rights reserved.
Convenient preparation of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors
作者:Yuli Xie、Gangli Gong、Yidong Liu、Shixian Deng、Alison Rinderspacher、Lars Branden、Donald W. Landry
DOI:10.1016/j.tetlet.2008.01.136
日期:2008.3
An efficient synthesis of a series of N-8-quinolinyl benzenesultarns as novel NF-kappa B inhibitors was described via diazotization-induced cyclization of easily accessible N-8-quinolinyl-2-aminobenzenesulfonamides. (C) 2008 Elsevier Ltd. All rights reserved.